INTRODUCTION
A transient period of hypercoagulability can occur during and after major orthopaedic surgery. 1, 2 There is no universally accepted postulate to account for this phase of haematologic homeostatic dysregulation. A safe and efficacious anticoagulation regimen is necessary, as the demands for joint replacement surgery worldwide, 3,4 the societal and patient demands for improved outcomes, and the need for evidencebased medicine-guided practices increase. [5] [6] [7] Both pharmacologic and non-pharmacologic options are available for prevention of venous thromboembolic events (VTEs). [8] [9] [10] [11] [12] The combined use of both confers synergistic utility, 3, 8, [12] [13] [14] whereas their individual use is rare. 9, 15 Optimisation of standards of care in nonpharmacologic approaches has been indicated. 3, 16 All available pharmacological thromboprophylaxis regimens have a risk profile. 3, 16, 17 The literature was reviewed to determine whether evidence-based support is sufficient to justify an extended course (>14 days) of anticoagulant prophylaxis after total hip replacement (THR). This study focused on the practical classification of VTEs and the optimal clinical 'window' (timeframe) for the use of anticoagulants.
METHODS
The PubMed (Medline), EMBASE, CINAHL and GoogleScholar, and the Cochrane and British Medical Journal Clinical Evidence libraries were searched using the key words: arthroplasty, total hip replacement, THR, thromboprophylaxis, and/or thrombo*.
VENOUS THROMBOEMBOLIC EVENTS
THR is a commonly performed and ever-increasing orthopaedic procedure worldwide. 16, [18] [19] [20] Its demand is driven by refinements in implant design and surgical technique, increase in population life-expectancy, and increase in patient expectations in functional quality of life. 19, 21, 22 Although THR can reduce pain and improve movement and function, 16, 20, [22] [23] [24] [25] it is an invasive procedure and has risks and complications, 26 particularly postoperative formation of intravascular blood clots. 16, [27] [28] [29] [30] [31] [32] VTEs can result in a high degree of morbidity and/or mortality related to pelvic and lower-limb deep vein thrombosis (DVT) and pulmonary embolism (PE). 8, [26] [27] [28] 31, [33] [34] [35] [36] [37] Without prophylaxis, VTE has an estimated incidence of 40 to 60%, 3, 17, [38] [39] [40] and an event rate warranting medical attention of 1.6 to 6.4%. 8, 27, 38, 40, 41 Stratification of the risks to identify patients most in need of vigilant monitoring or aggressive prophylactic therapy has been undertaken. 8, 42 Nonetheless, inconsistency in the definition of a VTE and disparity between clinical 43 and subclinical 44 (research) applications render comparisons between studies difficult, whereas biased statistical analysis may reflect both frank and sub-clinical VTEs. 7 Using invasive diagnostic tools, 37, 45, 46 the true prevalence of VTEs far exceeds that of patients who are symptomatic, 3, 10, 40, 47 which only serves to draw yet more attention to the induction of a hypercoagulable state after THR.
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EXTENDED COURSE OF THROMBOPROPHY-LAXIS
Recommendations for the duration of anti-VTE therapy vary from 14 to 42 days, 8, 27, 28, 32, 33, 37, 41, 42, [49] [50] [51] [52] [53] [54] but their translation into clinical practice has been inconsistent. 5, 14, 49, 55, 56 After THR, a thromboprophylactic regimen of >14 days has been advocated by many international bodies. For example the American College of Chest Physicians (ACCP) supports an extended course of prophylaxis with low-molecularweight heparin (LMWH) or warfarin for 28 to 35 days. 32, 39, 42, [56] [57] [58] [59] [60] [61] Compared with placebo, LMWH has been shown to reduce overall VTE rates significantly (Fig.) . 32 An extended course (4-6 weeks) of prophylaxis is superior to placebo in reducing the incidence of symptomatic VTEs (1.3% vs. 3.3%, p<0.05, relative risk reduction [RRR]=61%, number needed to treat [NNT]=50) as well as asymptomatic VTEs (9.6% vs. 19.6%, p<0.05, RRR=51%, NNT=10). 62 Compared with placebo, an extended course (4 weeks) of LMWH reduces the incidence of symptomatic VTEs from 4.2% to 1.4% (p<0.001, RRR=67%, NNT=36), and the overall rate from 22.5% to 7.9% (p<0.001, RRR=65%, NNT=7) [Table] . 5 Moreover, asymptomatic VTEs increase the risk of developing post-thrombotic syndrome (RR=2.36; 95% CI, 1.64-3.41; p<0.001). 63 The negative impact of extended courses of VTE prophylaxis on outcomes (i.e. number needed to harm [NNH] ) is difficult to determine, because of the low frequency of such adverse events. 7, 58 The rate of minor 
Figure
The incidence of deep vein thrombosis after total hip arthroplasty in patients receiving an extended course of low-molecular-weight heparin versus placebo, with a mean duration being 34 (range, 30-35) days.
bleeding after conventional anticoagulants has been quoted to be 4 to 5 times higher than with placebo, 37, 57 with a significant increase from 2.5 to 3.7% (RR increase=1.56; 95% CI, 1.08-2.26; NNH=83). 62 Minor bleeding events include subcutaneous bruising at the injection site and non-dramatic wound ooze. The major bleeding rate is about 2.5% (95% CI, 1-3%), 64 which is not significantly higher than that after placebo.
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Furthermore, major bleeding events occur even less frequently with longer duration of prophylaxis. The daily incidence rates were 1.8% within the first 5 days, and 0.3% after 7 days, and 0.1% at 10 days. 65 The efficacy and safety of such prophylaxis increase significantly (p=0.025) beyond 10 days. 66 An array of drugs are available for VTE prophylaxis, 3 (such as enoxaparin sodium). 13, 34, 37, 68, 70 Several newer agents targeting novel steps in the coagulation cascade have also been studied. 2, 3, 28, 45, 46, 69, 71 Each of these agents carries its own risk profile. 35, 42, 68, 72 Therefore, the benefit of VTE reduction must be weighed against the impact of potential adverse events, 72, 73 including excessive bleeding. 9, 13, 17, 67, 73 In addition, in a budgetdriven health care environment, cost-per-patient considerations 29, 51, 54, 69, 74 are important, especially in institutional practices. 3, 13, 70 There is no universally accepted single thromboprophylactic agent of choice. 3, 16, 17 Clinicians are advised to use those that they are most familiar with. An extended course (28-35 days) of enoxaparin sodium, delivered as a daily subcutaneous injection, 6,75 initiated on postoperative day one 38, 45, 46, 64 and continued for 4 weeks, is a popular choice, with reduction in DVT and PE rates being 40 to 72% and 46 to 65%, respectively. 62, [76] [77] [78] This agent can be administered to patients in an out-of-hospital setting (e.g. home-visit nursing services) as required, with limited need for haematologic monitoring. The efficacy and safety profile of enoxaparin has been extensively investigated. 34, 37, 47, 70, 74 Recent advances in oral preparations of LMWHs have simplified its delivery (especially in out-of-hospital settings), 3 but rigorous safety and efficacy appraisal is required.
LIMITATIONS
The protocol for the time to mobilisation, the use of mechanical anti-thrombotic devices, and the aggressiveness of early physiotherapy vary from institution to institution, as do initiation of preoperative thromboprophylaxis 64 and the length of hospital stay. All are related to the frequency of VTE events, but their absolute impact has not yet been supported by level I/II evidence. 64 Additional factors limiting generalisability include specialised patient management facilities (other than the expertise/resources available in general settings), small sample size, 37, 48, 50, 75 availability of highly sophisticated VTE monitoring approaches (related to external validity), 30, 45 poorly selected or absent of controls, 48 resorting to convenience (nonrandomised) sampling, 79 retrospective data, 80 poorly 5 defined methodology (limiting reproducibility), and the absence of adequate blinding.
CONCLUSION
There is robust evidence to support an extended course (>14 days) of thromboprophylaxis after THR, which confers a RRR of 0.33 to 0.41, even when weighed against the slight increase in adverse events.
Sound clinical acumen and judgement is nonetheless important. The extended regimen should provide a baseline, which can be adapted according to the specific circumstances (including clinical indication) of each patient. Clinicians are advised to use the pharmaceuticals that they are most familiar with to cover the high-risk window (postoperative days 14 to 35). The widely used LMWH (enoxaparin sodium) is convenient and reliable, and has a well-documented safety and efficacy profile.
